Pipeline

Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology.

Coming from a clear OTC focus in the last 15 years, we have decided to expand the applications of iota-carrageenan in the field of viral infectious diseases and focus our Marinosolv-based pipeline on therapies for immune disorders as we aim to provide physicians and patients with powerful therapies to significantly improve the patients' quality of life.

Therapeutic Area
Rx Segment
Indication and Product
Status
Pre Preclinical 1 Phase 1 2 Phase 2 3 Phase 3 Filing Filing

Herpetic stromal keratitis is a recurrent inflammation of the cornea that may result in corneal opacity and blindness. It affects about 400,000 people worldwide.

Learn more

Autoimmune gastritis is a chronic inflammatory disorder of the stomach lining which is characterized by the loss of parietal cells and consequently an increase of the pH value in the stomach. In addition, there is an increased risk of gastric cancer. The prevalence ranges from 0.33% and 0.49% in China resp. Japan up to 1.1% in the United States or 10.3% in Italy.

Learn more

Lower respiratory tract infections are a leading cause of death globally according to WHO. Highest burden of disease is in the very young, the very old, and in patients with chronic medical conditions, irrespective of the virus family.

Learn more
OTC Segment
Indication and Product
Status
Pre Preclinical 1 Phase 1 2 Phase 2 3 Phase 3 Filing Filing

Allergic rhinitis is caused by a hypersensitivity reaction caused to otherwise innocuous agents such as pollen or house dust mites. In the past decades, a globally rising trend of AR has been observed with up to 30% of the global population being potentially affected. 

In addition to Budesolv, Marinomed has developed a dissolved fluticasone propionate formulation that has potential in the allergy area similar to Budesolv.

Learn more

CarrageloseĀ® is a unique broadly active virus-blocking compound for treating respiratory diseases. Products containing this polymer have been approved for marketing in the EU, parts of Asia, Canada, and Australia.

Learn more

In addition to the active ingredient xylometazoline, the nasal spray also contains Carrageenan. It supports xylometazoline in reducing the duration and intensity of symptoms associated with viral infections of the respiratory tract.